JP6933378B2 - 三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル - Google Patents

三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル Download PDF

Info

Publication number
JP6933378B2
JP6933378B2 JP2018503548A JP2018503548A JP6933378B2 JP 6933378 B2 JP6933378 B2 JP 6933378B2 JP 2018503548 A JP2018503548 A JP 2018503548A JP 2018503548 A JP2018503548 A JP 2018503548A JP 6933378 B2 JP6933378 B2 JP 6933378B2
Authority
JP
Japan
Prior art keywords
fibroblasts
activity
fibroblast
cell
aggregate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018503548A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018535646A5 (https=
JP2018535646A (ja
Inventor
ホン キム，サン
ホン キム，サン
フン チェ，ジョン
フン チェ，ジョン
ドク パク，キ
ドク パク，キ
Original Assignee
エス−バイオメディックス
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エス−バイオメディックス filed Critical エス−バイオメディックス
Publication of JP2018535646A publication Critical patent/JP2018535646A/ja
Publication of JP2018535646A5 publication Critical patent/JP2018535646A5/ja
Priority to JP2021131745A priority Critical patent/JP7235350B2/ja
Application granted granted Critical
Publication of JP6933378B2 publication Critical patent/JP6933378B2/ja
Priority to JP2023022415A priority patent/JP7525939B2/ja
Priority to JP2024111522A priority patent/JP7727339B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0652—Cells of skeletal and connective tissues; Mesenchyme
    • C12N5/0656—Adult fibroblasts
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/78—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin or cold insoluble globulin [CIG]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0697—Artificial constructs associating cells of different lineages, e.g. tissue equivalents
    • C12N5/0698—Skin equivalents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/115—Basic fibroblast growth factor (bFGF, FGF-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2513/00—3D culture
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2533/00—Supports or coatings for cell culture, characterised by material
    • C12N2533/50—Proteins
    • C12N2533/52—Fibronectin; Laminin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
JP2018503548A 2015-11-12 2016-04-19 三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル Active JP6933378B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2021131745A JP7235350B2 (ja) 2015-11-12 2021-08-12 マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
JP2023022415A JP7525939B2 (ja) 2015-11-12 2023-02-16 Ｍｂｐ－ｆｇｆ組み換えタンパク質を用いた三次元線維芽細胞集合体の調製、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル
JP2024111522A JP7727339B2 (ja) 2015-11-12 2024-07-11 コラーゲン発現量が制御された三次元線維芽細胞集合体を生成する方法、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
KR1020150159011A KR20170055791A (ko) 2015-11-12 2015-11-12 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
KR10-2015-0159011 2015-11-12
PCT/KR2016/004043 WO2017082491A1 (ko) 2015-11-12 2016-04-19 3차원 섬유아세포집합체 및 그를 포함하는 인 비트로 3d 피부 진피 모델

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2021131745A Division JP7235350B2 (ja) 2015-11-12 2021-08-12 マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル

Publications (3)

Publication Number Publication Date
JP2018535646A JP2018535646A (ja) 2018-12-06
JP2018535646A5 JP2018535646A5 (https=) 2019-05-30
JP6933378B2 true JP6933378B2 (ja) 2021-09-08

Family

ID=58695687

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2018503548A Active JP6933378B2 (ja) 2015-11-12 2016-04-19 三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
JP2021131745A Active JP7235350B2 (ja) 2015-11-12 2021-08-12 マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
JP2023022415A Active JP7525939B2 (ja) 2015-11-12 2023-02-16 Ｍｂｐ－ｆｇｆ組み換えタンパク質を用いた三次元線維芽細胞集合体の調製、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル
JP2024111522A Active JP7727339B2 (ja) 2015-11-12 2024-07-11 コラーゲン発現量が制御された三次元線維芽細胞集合体を生成する方法、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2021131745A Active JP7235350B2 (ja) 2015-11-12 2021-08-12 マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
JP2023022415A Active JP7525939B2 (ja) 2015-11-12 2023-02-16 Ｍｂｐ－ｆｇｆ組み換えタンパク質を用いた三次元線維芽細胞集合体の調製、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル
JP2024111522A Active JP7727339B2 (ja) 2015-11-12 2024-07-11 コラーゲン発現量が制御された三次元線維芽細胞集合体を生成する方法、及び当該線維芽細胞集合体を含むインビトロ３ｄ皮膚真皮モデル

Country Status (6)

Country Link
US (1) US10725043B2 (https=)
EP (1) EP3375865A4 (https=)
JP (4) JP6933378B2 (https=)
KR (1) KR20170055791A (https=)
CN (2) CN113583946B (https=)
WO (1) WO2017082491A1 (https=)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20170055791A (ko) * 2015-11-12 2017-05-22 한국과학기술연구원 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
KR102213922B1 (ko) * 2017-06-30 2021-02-08 (주)아모레퍼시픽 인공피부 제조방법 및 인공피부
EP3708653A4 (en) * 2017-11-10 2021-08-18 Toppan Printing Co., Ltd. ARTIFICIAL ADAPTIVE TISSUE AND METHOD FOR MANUFACTURING THEREOF, METHOD FOR MANUFACTURING ARTIFICIAL SKIN AND AGENTS FOR FAT CELLS
CN108795867A (zh) * 2018-06-05 2018-11-13 华东理工大学 用于构建结肠癌细胞腹膜转移体外三维模型的方法
WO2022024886A1 (ja) * 2020-07-27 2022-02-03 株式会社コーセー 全分泌調節剤の評価及び／又は選択方法
KR102365125B1 (ko) * 2020-08-12 2022-02-18 주식회사 티앤알바이오팹 인공 피부 모델을 사용한 피부 탄성 측정 방법 및 피부 첨가제의 스크리닝 혹은 선별 방법
CN114107429A (zh) * 2021-12-02 2022-03-01 云南贝泰妮生物科技集团股份有限公司 一种化妆品原料体外3d皮肤模型屏障修复功效的筛选方法
CN114292894B (zh) * 2022-01-14 2023-08-11 广东悠质检测技术有限公司 一种用体外细胞评价化妆品及原料紧致功效的方法
CN119286771A (zh) * 2024-10-28 2025-01-10 深圳锦时生物科技有限公司 一种高效分离自体皮肤来源的成纤维细胞培养方法

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH03266980A (ja) 1989-03-16 1991-11-27 W R Grace & Co 細胞培養用基材およびそれを用いた細胞集合体の製造方法
JPH0489000A (ja) * 1990-05-02 1992-03-23 W R Grace & Co 細胞培養キットおよび細胞傷害試験法
JP4751005B2 (ja) * 2000-05-31 2011-08-17 フラウンホファー ゲセルシャフト ツール フェールデルンク ダー アンゲヴァンテン フォルシュンク エー．ファオ． 三次元皮膚モデル
JP3709369B2 (ja) 2001-11-13 2005-10-26 丸善製薬株式会社 皮膚化粧料及び美容用飲食品
DE102004039537A1 (de) * 2004-08-13 2006-02-23 Phenion Gmbh & Co. Kg Vernetzte Kollagenmatrix zur Herstellung eines Hautäquivalentes
JP4792566B2 (ja) 2005-06-01 2011-10-12 財団法人ヒューマンサイエンス振興財団 樹状細胞を含む三次元培養ヒト皮膚モデル
JP2010172240A (ja) * 2009-01-28 2010-08-12 Shiseido Co Ltd エラスチン発現低下を回復する薬剤のスクリーニング方法
JP2010193822A (ja) 2009-02-26 2010-09-09 Toyobo Co Ltd ３次元培養細胞により作成した皮膚同等物およびそれを用いる紫外線の影響の評価方法
KR101094445B1 (ko) 2009-05-13 2011-12-15 한국과학기술연구원 줄기세포에 대한 접착활성을 갖는 섬유아세포 성장인자의 재조합 단백질 및 이를 이용한 줄기세포의 배양방법
JP2012050406A (ja) 2010-09-03 2012-03-15 Genesis Healthcare Kk 皮膚関連遺伝子の検出方法、並びに該遺伝子を用いた肌情報の提供方法、化粧品の販売システム、化粧品の販売方法及び化粧品成分のスクリーニング方法
CN104263698B (zh) * 2014-09-19 2016-05-18 江苏华亿细胞组织工程有限公司 临床治疗级细胞治疗用成纤维细胞规模化制备人类细胞外基质筛选培养方法
KR20170055791A (ko) 2015-11-12 2017-05-22 한국과학기술연구원 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법

Also Published As

Publication number Publication date
JP2024133695A (ja) 2024-10-02
CN107002032B (zh) 2021-08-27
CN107002032A (zh) 2017-08-01
JP7525939B2 (ja) 2024-07-31
JP7727339B2 (ja) 2025-08-21
JP2023058684A (ja) 2023-04-25
US10725043B2 (en) 2020-07-28
US20180252715A1 (en) 2018-09-06
JP2018535646A (ja) 2018-12-06
JP7235350B2 (ja) 2023-03-08
EP3375865A1 (en) 2018-09-19
CN113583946B (zh) 2024-11-08
WO2017082491A1 (ko) 2017-05-18
EP3375865A4 (en) 2019-07-10
JP2021180681A (ja) 2021-11-25
CN113583946A (zh) 2021-11-02
KR20170055791A (ko) 2017-05-22

Similar Documents

Publication Publication Date Title
JP7235350B2 (ja) マルトース結合タンパク質リンカを用いた三次元線維芽細胞集合体、及びそれを含むインビトロ３ｄ皮膚真皮モデル
El-Rashidy et al. Effect of polymeric matrix stiffness on osteogenic differentiation of mesenchymal stem/progenitor cells: concise review
Jain et al. Mimicking the natural basement membrane for advanced tissue engineering
Prestwich Evaluating drug efficacy and toxicology in three dimensions: using synthetic extracellular matrices in drug discovery
US9644183B2 (en) Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same
Recha‐Sancho et al. Heparin‐based self‐assembling peptide scaffold reestablish chondrogenic phenotype of expanded de‐differentiated human chondrocytes
Lyu et al. Graphene hydrogel as a porous scaffold for cartilage regeneration
Rengaraj et al. Engineering of a microscale niche for pancreatic tumor cells using bioactive film coatings combined with 3D-architectured scaffolds
LaNasa et al. Influence of ECM proteins and their analogs on cells cultured on 2-D hydrogels for cardiac muscle tissue engineering
Huang et al. Engineering a self-assembling leucine zipper hydrogel system with function-specific motifs for tissue regeneration
KR101919930B1 (ko) 인 비트로 3차원 세포 배양 모델, 이의 제조 방법 및 이를 이용한 스크리닝 방법
Scott et al. Three-dimensional cell entrapment as a function of the weight percent of peptide-amphiphile hydrogels
WO2010110596A2 (en) Method for differentiation of stem cells into vascular cells and the induction of angiogenesis using the same
KR102261934B1 (ko) Mbp-fgf2를 이용한 3차원 섬유아세포집합체를 제조하는 방법
KR102066670B1 (ko) 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
HK40056234A (en) Three-dimensional fibroblast aggregate and in vitro 3d skin dermis model comprising same
HK40056234B (zh) 三维成纤维细胞集合体及包含此的体外三维皮肤真皮模型
Dabaghi et al. A roadmap for developing and engineering in vitro pulmonary fibrosis models
KR102236977B1 (ko) 3차원 섬유아세포집합체 및 그의 생산방법
KR20170132121A (ko) 인 비트로 3ｄ 피부 진피 모델 및 그를 사용하여 약물을 스크리닝하는 방법
Ghosh et al. Cell-Material Interaction in Sustainable Biomedical Engineering
Sari et al. Targeting Mechanobiology of Stem Cells Via Biomaterials for Regenerative Medicine Approaches
Mukherjee et al. Cell-Material Interaction in Sustainable
Devarajan et al. Decellularized extracellular matrix as a three-dimensional platform for in vitro tumour modelling: a comprehensive review
Wang Signaling from matrix elasticity and TGF-β1 to cells of the cardiac valve

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190419

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190419

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200128

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200427

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20200601

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200601

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200923

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20201217

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210224

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210713

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210812

R150 Certificate of patent or registration of utility model

Ref document number: 6933378

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250